Prescribing of psychotropic medications to the elderly population of a Canadian province: A retrospective study using administrative databases

PeerJ

Volumn 2013, Issue 1, 2013, Pages

  Alessi Severini, Silvia ^a   Dahl, Matthew ^a   Schultz, Jennifer ^b   Metge, Colleen ^b   Raymond, Colette ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DONEPEZIL; GALANTAMINE; MEMANTINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ZALEPLON; ZOPICLONE;

AGED; ARTICLE; BEHAVIOR CHANGE; CANADA; COMORBIDITY; DEMOGRAPHY; DRUG MEGADOSE; DRUG USE; ELDERLY CARE; FEMALE; HUMAN; ICD-10-CM; ICD-9-CM; INCIDENCE; MALE; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; SOCIAL STATUS;

EID: 84885113021     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.168     Document Type: Article

References (41)

1. Alessi-Severini S, Biscontri RG, Collins DM, Kozyrskyj A, Sareen J, Enns MW. 2008. Utilization and costs of antipsychotic agents: a Canadian population-based study: 1996-2006. Psychiatric Services 59(5):547-553 DOI 10.1176/appi.ps.59.5.547.
2. APAWork Group on Alzheimer's Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM, Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Schneidman B, Summergrad P, Woods SM, Berger J, Cross CD, Brandt HA, Margolis PM, Shemo JP, Blinder BJ, Duncan DL, Barnovitz MA, Carino AJ, Freyberg ZZ, Gray SH, Tonnu T, Kunkle R, Albert AB, Craig TJ, Regier DA, Fochtmann LJ. 2007. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. The American Journal of Psychiatry 164(12 Suppl):5-56.
3. Ayer A, Antic V, Dulloo AG, Van Vliet BN, Montani JP. 2007. Hemodynamic consequences of chronic parasympathetic blockade with a peripheral muscarinic antagonist. American Journal of Physiology - Heart and Circulatory Physiology 293(2):H1265-H1272 DOI 10.1152/ajpheart.00326.2007.
4. Barlett G, Abrahamowicz M, Grad R, Sylvestre M-P, Tamblyn R. 2009. Association471-2296-10-1. Barlett between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons. BMC Family Practice 10:1-8 DOI 10.1186/1
5. Chan W, Lam LC, Chen EY. 2011. Recent advances in pharmacological treatment of psychosis in late life. Current Opinion in Psychiatry 24:455-460 DOI 10.1097/YCO.0b013e32834a3f47.
6. Doupe M, Brownell M, Kozyrskyj A, Dik N, Burchill C, Dahl M, Chateau D, De Coster C, Hinds A, Bodnarchuk, J. 2006. Using administrative data to develop indicators of quality care in personal care homes. Manitoba Centre for Health Policy. Available at http://mchp-appserv.cpe.umanitoba.ca/reference/pch.qi.pdf (accessed 8 May 2013).
7. Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. 2000. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke 31(10):2307-2313 DOI 10.1161/01.STR.31.10.2307.
8. EuropeanMedicines Agency (EMEA). 2009. Safety aspects of antipsychotics in demented patients. Available at http://www.ema.europa.eu/docs/enGB/documentlibrary/Other/2010/03/WC500076323.pdf (accessed 21 June 2013).
9. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy JP, CCCDTD4 participants. 2012. 4th Canadian consensus conference on the diagnosis and treatment of dementia. Canadian Journal of Neurological Sciences 39(Suppl 5):S1-S8.
10. Health Canada. 2002. Important drug safety information: RISPERDAL* (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials-janssen-ortho inc. Available at http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2002/14164a-eng.php (accessed 1 May 2013).
11. Health Canada. 2004. ZYPREXA (olanzapine) and cerebrovascular adverse events in placebo-controlled elderly dementia trials. Available at http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2004/14300a-eng.php (accessed 21 June 2013).
12. Health Canada. 2005. Increased mortality associated with the use of atypical antipsychotic drugs in elderly patients with dementia. Available at http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/13696a-eng.php (accessed 1 May 2013).
13. Health Canada. 2013. Drug product database. Available at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php (accessed 11 July 2013).
14. Hill KD, Wee R. 2012. Psychotropic drug-induced falls in older people. Drugs Aging 29(1):15-30 DOI 10.2165/11598420-000000000-00000.
15. International Classification of Diseases. 2013. Clinical Modification, Version 9 and Version 10 (ICD-9-CM and ICD-10-CM codes). Available at http://www.icd9data.com (accessed 11 July 2013).
16. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K. 2008. ACNP White Paper: update on use of antipsychotic drugs in older adults with dementia. Neuropsychopharmacology 33(5):957-970 DOI 10.1038/sj.npp.1301492.
17. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, Ganoczy D, Cunningham F, Schneider LS, Blow FC. 2011. Trends in antipsychotic use in dementia 1999-2007. Archives of General Psychiatry 68(2):190-197 DOI 10.1001/archgenpsychiatry.2010.200.
18. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. 2004. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 329(7457):75 DOI 10.1136/bmj.38125.465579.55.
19. Leslie DL, Rosenheck R. 2012. Off-label use of antipsychotic medications in Medicaid. American Journal of Management Care 18(3):e109-e117.
20. Martinez C, Jones RW, Rietbrock S. 2013. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open 3:e002080 DOI 10.1136/bmjopen-2012-002080.
21. Mehta S, Johnson ML, Chen H, Aparasu RR. 2010. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Journal of Clinical Psychiatry 71(6):689-698 DOI 10.4088/JCP.09m05817yel.
22. Mittal V, Kurup L, Williamson, Muralee S, Tampi RR. 2011. Risk of cerebrovascular adverse events and death in elderly patients with dementia treated with antipsychotic medications: a literature review of evidence. American Journal of Alzheimer's Disease & Other Dementias 26:10-28 DOI 10.1177/1533317510390351.
23. Peisah C, Chan DKY, McKay R, Kurrle SE, Reutens SG. 2011. Practical guidelines for the acute emergency sedation of the severely agitated older patient. Internal Medicine Journal 41:651-657 DOI 10.1111/j.1445-5994.2011.02560.x.
24. Percudani M, Barbui C, Fortino I, Tansella M, Petrovich L. 2005. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Journal of Clinical Psychopharmacology 25(5):468-470 DOI 10.1097/01.jcp.0000178414.14685.c4.
25. Personal Health Information Act ofManitoba. 2013. Available at http://www.gov.mb.ca/health/phia/(accessed 21 June 2013).
26. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. 2001. Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 58(12):1161-1167 DOI 10.1001/archpsyc.58.12.1161.
27. Reid RJ, MacWilliam L, Roos NP, Bogdanovic B, Black C. 1999. Measuring morbidity in populations: performance of the Johns Hopkins adjusted clinical group (ACG) case-mix adjustment system in Manitoba. In: Manitoba centre for health policy and evaluation. Winnipeg, MB: University of Manitoba. Available at http://mchp-appserv.cpe.umanitoba.ca/reference/acg.pdf.
28. Sacchetti E, Turrina C, Valsecchi P. 2010. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Safety 33(4):273-288 DOI 10.2165/11319120-000000000-00000.
29. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. 2007. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal 176(5):627-632 DOI 10.1503/cmaj.061250.
30. Schulze J, van den Bussche H, Glaeske G, Kaduszkiewicz H, Wiese B, Hoffmann F. 2013. Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. European Neuropsychopharmacology DOI 10.1016/j.euroneuro.2013.02.001.
31. Statistics Canada. 2013. Population, urban and rural, by province and territory (Manitoba). Available at http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo62h-eng.htm (accessed 11 July 2013).
32. Tariot PN. 2004. Clinical effectiveness of atypical antipsychotics in dementia. Journal of Clinical Psychiatry 65(Suppl 11):3-4.
33. The Canadian Institute for Health Information. 2009. Antipsychotic use in seniors: an analysis focusing on drug claims, 2001 to 2007. Available at https://secure.cihi.ca/estore/productFamily.htm?pf=PFC1350&lang=en&media=0 (accessed 16 November 2012).
34. The Food and Drug Administration. 2008. FDA requests boxed warnings on older class of antipsychotic drugs. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm (accessed 21 June 2013).
35. TheManitoba Centre for Health Policy. 2013. Concept: adjusted clinical group (ACG)-overview. Available at www.umanitoba.ca/faculties/medicine/units/mchp/resources/glossary.html (accessed 1 May 2013).
36. Trifiro G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. 2007. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiology and Drug Safety 16(5):538-544 DOI 10.1002/pds.1334.
37. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. 2008. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. Canadian Medical Association Journal/Journal de l'Association Medicale Canadienne 179(5):438-446 DOI 10.1503/cmaj.071540.
38. Vasilyeva I, Biscontri RG, Enns MW, Metge CJ, Alessi-Severini S. 2013. Adverse events in elderly users of antipsychotic pharmacotherapy in the province of Manitoba: a retrospective cohort study. Journal of Clinical Psychopharmacology 33(1):24-30 DOI 10.1097/JCP.0b013e31827934a4.
39. VittinghoffE, Glidden DV, Shiboski SC, McCulloch CE. 2012. Regression methods in biostatistics-statistics for biology and health, Second Edition. NY: Springer Science+Business Media.
40. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. 2005. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. The New England Journal of Medicine 353(22):2335-2341 DOI 10.1056/NEJMoa052827.
41. World Health Organization. 2013. WHO Collaborating Centre for Drug Statistics Methodology ATT/DD Index 2013. Available at http://www.whocc.no/atcddd (accessed 1 May 2013).